Science Progress (1933-), Vol. 104, No. 1 (2021), pp. 1-16 (17 pages) Drug-induced liver injury (DILI) is one of the common adverse drug reactions and the leading cause of drug development attritions, ...

Abstract and Introduction Current Status of DILI Biomarkers Promising Avenues for Discovery of New DILI Biomarkers Next Steps References The lymphocyte transformation test is commercially available in ...

There is a pressing need for new clinical tests that will help physicians distinguish drug-induced liver injury (DILI) from other, more common causes of liver injury, and that can identify which ...

The integrated analysis of serum and fecal metabolites uncovers the significant disruption of bile acid metabolites as a key contributing factor in the pathogenesis of DILI. Our study offers promising ...

Critical Path Institute (C-Path) announced today that the Biomarker Qualification Program (BQP) at the Center for Drug Evaluation and Research (CDER) from the U.S. Food and Drug Administration (FDA) ...

Caption The integrated analysis of serum and fecal metabolites uncovers the significant disruption of bile acid metabolites as a key contributing factor in the pathogenesis of DILI. Our study offers ...

Understanding advances in current biomarker design helps to guide appropriate application of immunotherapy. Tumoral complexity, clonal evolution, and heterogenous host immune defects limit the utility ...